Skip to main content

Binding of Reactive Brilliant Red to Human Serum Albumin: Insights into the Molecular Toxicity of Sulfonic Azo Dyes

Buy Article:

$55.00 plus tax (Refund Policy)

The non-covalent interaction of reactive brilliant red (RBR) as a representative of sulfonic azo compounds with human serum albumin (HSA) was investigated by a combination of UV-VIS spectrometry, fluorophotometry, circular dichroism (CD) and isothermal titration calorimetry (ITC) technique. The thermodynamic characterization of the interaction was performed. The saturation binding numbers of RBR on peptide chains were determined and the effects of electrolytes and temperature were investigated. The ionic interaction induced a combination of multiple non-covalent bonds including hydrogen bonds, hydrophobic interactions and van der Waals force. A three-step binding model of RBR was revealed. The binding of RBR molecules might occur on the external surface of HSA via electric interaction when the mole ratio of RBR to HSA was less than 40 and RBR molecules entered the hydrophobic intracavity of HSA when the ratio was more than 40. Moreover, RBR binding resulted in a conformational change in the structure of HSA or even the precipitation of HSA and inhibited its function accordingly. The possible binding site and the conformational transition of HSA were hypothesized and illustrated. This work provides a new insight into non-covalent interaction between a sulfonic azo compound and protein, which may be further used to investigate the potential toxicity of azo dyes.





No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Non-covalent interaction; human serum albumin; reactive brilliant red

Document Type: Research Article

Publication date: 2010-05-01

More about this publication?
  • Protein & Peptide Letters publishes short papers in all important aspects of protein and peptide research, including structural studies, recombinant expression, function, synthesis, enzymology, immunology, molecular modeling, drug design etc. Manuscripts must have a significant element of novelty, timeliness and urgency that merit rapid publication. Reports of crystallisation, and preliminary structure determinations of biologically important proteins are acceptable. Purely theoretical papers are also acceptable provided they provide new insight into the principles of protein/peptide structure and function.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more